Reports Q3 revenue $11M, consensus $15.5M. Cash and cash equivalents as of September 30, 2025 were $56.4 million. The company continues to expect that its capital resources will be sufficient to support its current operating plan commitments into mid-2026
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRSN:
- Mersana Therapeutics downgraded to Market Perform from Outperform at William Blair
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
- Mersana Therapeutics downgraded to Neutral from Buy at Guggenheim
- Mersana downgraded to Market Perform from Outperform at LifeSci Capital
- Hold Rating on DAWN’s Acquisition of Mersana Therapeutics: Balancing Opportunities and Risks Amid ACC Focus